Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications (link to LDN patents), is currently used as an immune modulator.
OGF/MENK has been shown to halt the growth of the cells and is thought to allow immunological mechanisms (e.g. macrophages, natural killer cells) to accomplish the task of destroying the cancerous cells.
ORLANDO, FL AND DUBLIN, IRELAND / ACCESSWIRE / January 21, 2016 / Immune Therapeutics Inc., a U.S. public company (OTCQB: IMUN) today announced that it has completed its 90-day bridging trail of Human Immunodeficiency Virus positive [HIV+] patients and submitted data to The National Agency for Food and Drug Administration and Control, (NAFDAC) in connection with the approval of LodonalTM as an immune booster that can improve the health of those effected by human immunodeficiency virus [HIV+] and people with a comprised immune systems. The primary objectives of the clinical trial was to confirm that LodonalTM is first and foremost safe for use in the local population and secondly has a beneficial effect on the immune system of patients with a compromised immune system such as HIV+ individuals. Immune enhancement and/or balance will be determined by the number of subjects receiving LodonalTM with CD4 count stabilization (less than 10% change from baseline mean values) or 25% increase in CD4 counts on LodonalTM compared to placebo group from baseline.
ORLANDO, FL / ACCESSWIRE / January 11, 2016 / Immune Therapeutics Inc. (OTCQB: IMUN) CEO, Noreen Griffin, will be making a presentation at today’s JP Morgan Health Conference at the Fairmont hotel in San Francisco.
Her 30 minute presentation, which begins at 3:30 p.m. PST, will provide an overview of the company’s major 2015 milestones and will include the outlook for 2016. Immune Therapeutics will showcase the Company’s groundbreaking treatments for cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases, and showcase the 2016 product roadmap and global distribution strategy. The Company will also be participating in 1-on-1 meetings throughout the day.
ORLANDO, FL / ACCESSWIRE / October 7, 2015 / Immune Therapeutics Inc. a specialty biopharmaceutical company (IMUN) today provided an update on the ongoing clinical trial of Lodonal in Nigeria.
The trial is an open-label, placebo-controlled study that includes a 90-day treatment period followed by a 60-day extension. The primary objective of this clinical trial is to confirm that Lodonal has a beneficial effect on the immune system of patients in Nigeria with a compromised immune system (refer to Inclusion/Exclusion Criteria). This will be determined by: the number of subjects on Lodonal who achieve CD4 count stabilization (less than 10% change from baseline mean values) or a 25% increase in CD4 counts when compared to the observation group from baseline to Days 30, 60 and 90.